TriSalus Life Sciences(TLSI) - 2025 Q2 - Quarterly Results

DENVER – August 12, 2025 - TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June 30, 2025, and provides an operation update. "TriSalus continued to deliver strong commercial momentum in the second quarter, underscoring the growing clinical adoption of our ...